There are a growing number of therapeutic options for JIA, including IL-1, IL-6, JAK inhibitors, and biologics that simultaneously target IL-18, interferon gamma, or IL-1β and IL-18. This evidence concerns the gene IL18 and juvenile idiopathic arthritis.